Document:

EX-4.2

  Exhibit 4.2

  DESCRIPTION OF SECURITIES

   

  General

   

  The following summary describes our securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), certain provisions of our certificate of incorporation and bylaws, and certain provisions of Delaware law. Because it is only a summary, it does not contain all of the information that may be important to you. For a complete description of the matters set forth in this Description of Securities, you should refer to our amended and restated certificate of incorporation, as amended (“Restated Certificate”), amended and restated bylaws (“Bylaws”), each of which are filed as exhibits to the Annual Report on Form 10-K of which this exhibit is a part, as well as the relevant provisions of the Delaware General Corporation Law (“DGCL”). The Restated Certificate authorizes us to issue 300,000,000 shares of common stock, par value $0.01 per share, and 7,000,000 shares of preferred stock, par value $0.01 per share. Our board of directors has designated 1,000,000 shares of the preferred stock as Series A 4.5% Convertible Preferred Stock (the “Series A 4.5% Preferred Stock”) of which 200,000 shares are issued and outstanding as of the date of the Annual Report on Form 10-K of which this exhibit is a part. The holders of Series A 4.5% Preferred Stock shall have no voting rights but shall be entitled to appoint one member to our Board. This right to appoint a member of the Board will terminate when there are less than 200,000 shares of Series A 4.5% Preferred Stock outstanding. As long as any shares of Series A 4.5% Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A 4.5% Preferred Stock, alter or change adversely the powers, preferences or rights given to the Series A 4.5% Preferred Stock or alter or amend the Certificate of Designation, other than to authorize and issue additional shares of Series A 4.5% Preferred Stock. In addition, holders of Series A 4.5% Preferred Stock are subject to beneficial ownership limitations, as provided in the Certificate of Designation of Series A 4.5% Convertible Preferred Stock (the “Certificate of Designation”). 

   

  Our board of directors has the authority, without stockholder approval, except as required by the listing standards of The Nasdaq Stock Market LLC, to issue additional shares of our capital stock. In addition, our board of directors has the authority, without further action by our stockholders, to designate the rights, preferences, privileges, qualifications and restrictions of our preferred stock in one or more series.

   

  Common Stock

   

  Voting Rights

  Our common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and does not have cumulative voting rights.

   

  Economic Rights

  Except as otherwise expressly provided in the Restated Certificate or required by applicable law, all shares of common stock have the same rights and privileges and rank equally, share ratably, and are identical in all respects for all matters, including those described below.

   

  Dividends. Subject to preferences that may be applicable to any then-outstanding preferred stock, including the Series A 4.5% Preferred Stock, the holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.

   

  Liquidation Rights. In the event of our liquidation, dissolution or winding-up, holders of our common stock are entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock.

   

  

   

  No Preemptive or Similar Rights

   

  The holders of our shares of common stock are not entitled to preemptive rights, and are not subject to conversion, redemption or sinking fund provisions. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.

   

  Fully Paid and Non-Assessable

  All of our outstanding shares of common stock are fully paid and nonassessable.

   

  Anti-Takeover Provisions

  The provisions of the DGCL, the Restated Certificate and the Bylaws, certain provisions of which are summarized below, may have the effect of delaying, deferring or discouraging another person from acquiring control of our company. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.

   

  Delaware Anti-Takeover Law

   

  We are subject to Section 203 of the DGCL, which generally prohibits a public Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:

   

  •prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

  •the interested stockholder owned at least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

  •on or subsequent to the consummation of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.

   

  Section 203 of the DGCL defines a business combination to include:

  •any merger or consolidation involving the corporation and the interested stockholder;

  •any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;

  •subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder;

  •subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; and

   

  265992896 v2

   

  

  •the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

   

  In general, Section 203 of the DGCL defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.

   

  Certificate of Incorporation and Bylaws

   

  Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the voting power of our shares of common stock may be able to elect all of our directors. The Restated Certificate and the Restated Bylaws provide for stockholder actions at a duly called meeting of stockholders or, before the date on which all shares of common stock convert into a single class, by written consent. A special meeting of stockholders may be called by a majority of our board of directors, the chair of our board of directors, or our chief executive officer. The Bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors. Our board of directors is divided into three classes with staggered three-year terms.

   

  The foregoing provisions may make it difficult for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.

   

  These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts.

   

   

  265992896 v2EX-10.5

  EXHIBIT 10.5

  CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

   

   

  LICENSE AGREEMENT

   

   

   

  BETWEEN

   

   

   

  PALISADE BIO, INC.

   

   

  AND

   

   

   

  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

   

   

   

  FOR

   

   

   

  CASE NO.  [***]

  CASE NO.  [***]

   

   

   

  	 

  ***Certain Confidential Information Omitted

  Page 1 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  TABLE OF CONTENTS

   

  Recitals											3

   

  Article 1:	Definitions 								4

   

  Article 2:	Grants 									6

   

  Article 3: 	Consideration							8

   

  Article 4: 	Reports, Records and Payments			11

   

  Article 5: 	Patent Matters							14

   

  Article 6:	Governmental Matters						17

   

  Article 7:	Termination or Expiration of Agreement		17

   

  Article 8:	Limited Warranty and Indemnification			18

   

  Article 9:	Use of Names and Trademarks				21

   

  Article 10:	Miscellaneous Provisions				21

   

  Exhibit A:	Due Diligence Obligations				25

   

   

   

   

    

   

   

  	 

  ***Certain Confidential Information Omitted

  Page 2 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  LICENSE AGREEMENT

   

   

  This agreement (“Agreement”) is made by and between Palisade Bio, Inc., a Delaware corporation having an address at 5800 Armada Dr, Suite 210, Carlsbad, California 92008 (together with its Affiliates, including Leading BioSciences, Inc., “LICENSEE”) and The Regents of the University of California, a California public corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UCSD”).

   

  This Agreement is effective on the date of the last signature (“Effective Date”).

   

   

  RECITALS

   

  WHEREAS, the inventions disclosed in UCSD Disclosure Docket No.  [***], and in UCSD Disclosure Docket No. [***] (collectively “Invention”), were made in the course of research at UCSD by [***] and associates (hereinafter and collectively, the “Inventors”) and are covered by Patent Rights as defined below;

   

  WHEREAS, the Inventors are employees of UCSD, and they are obligated to assign all of their right, title and interest in the Invention to UNIVERSITY;

    

  WHEREAS, UNIVERSITY is desirous that the Invention be developed and utilized to the fullest possible extent so that its benefits can be enjoyed by the general public;

   

  WHEREAS, LICENSEE previously entered into License Cont. No. [***], having an effective date of April 1, 2020, to acquire certain rights from UNIVERSITY for commercial development, use, and sale of the Invention; 

   

  WHEREAS, LICENSEE is now desirous of obtaining additional  rights from UNIVERSITY for commercial development, use, and sale of the Invention, including in the field of cancer, and the UNIVERSITY is willing to grant such rights; and

   

  WHEREAS, LICENSEE understands that UNIVERSITY may publish or otherwise disseminate information concerning the Invention at any time and that LICENSEE is paying consideration thereunder for its early access to the Invention, not continued secrecy therein.

   

  NOW, THEREFORE, the parties agree:

   

   

  Remainder of page intentionally left blank.

   

  	 

  ***Certain Confidential Information Omitted

  Page 3 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  ARTICLE 1.  DEFINITIONS

   

  The terms, as defined herein, shall have the same meanings in both their singular and plural forms.

   

  1.1	“Affiliate” means any corporation or other business entity in which LICENSEE owns or controls, directly or indirectly, at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors, or in which LICENSEE is owned or controlled directly or indirectly by at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors; but in any country where the local law does not permit foreign equity participation of at least fifty percent (50%), then an “Affiliate” includes any company in which LICENSEE owns or controls or is owned or controlled by, directly or indirectly, the maximum percentage of outstanding stock or voting rights permitted by local law.

   

  1.2	“Combination Product” means any product which is a Licensed Product (as defined below) and contains other product(s) or product component(s) that is not an excipient, diluent, adjuvant, buffer and the like and (i) does not use Invention or Patent Rights (as defined below); (ii) the sale, use or import by itself does not contribute to or induce the infringement of Patent Rights; (iii) is sold separately by LICENSEE, its Sublicensee (as defined below) or an Affiliate; and (iv) enhances the market price of the final product(s) sold, used or imported by LICENSEE, its Sublicensee, or an Affiliate.

   

  1.3	“Field” means [***].

  1.4	Deleted.

   

  1.5	“Licensed Method” means any method that is claimed in Patent Rights (as defined below), the use of which would constitute, but for the license granted to LICENSEE under this Agreement, an infringement, an inducement to infringe or contributory infringement, of any pending or issued claim within Patent Rights.  

   

  1.6	“Licensed Product” means any service, machine, manufacture, composition of matter, or other product that is claimed in Patent Rights, or that includes the practice of methodology under the Licensed Methods, or the manufacture, use, sale, offer for sale, or importation of which would constitute, but for the license granted to LICENSEE under this Agreement, an infringement, an inducement to infringe or contributory infringement, of any pending or issued claim within the Patent Rights.

   

  Remainder of page intentionally left blank. 

   

   

   

  	 

  ***Certain Confidential Information Omitted

  Page 4 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  1.7	“Net Sales” means the total of the gross invoice prices of Licensed Products sold or leased by LICENSEE, Sublicensee, Affiliate, or any combination thereof, less the sum of the following actual and customary deductions where applicable and separately listed:  [***].  For purposes of calculating Net Sales, [***]. Notwithstanding the foregoing, [***], shall be disregarded in determining Net Sales.  

   

  1.8	[Intentionally Omitted]

   

  1.9	“Patent Costs” means all expenses for the preparation, filing, prosecution, and maintenance of all United States and foreign patents included in Patent Rights.  Patent Costs shall also include out-of-pocket expenses for patentability opinions, inventorship determination, preparation and prosecution of patent application, re-examination, re-issue, interference, and opposition activities related to patents or applications in Patent Rights.  

   

  1.10	“Patent Rights” means UNIVERSITY’s rights in any of the following: 

  (1) all patent rights associated with UCSD Case File [***]; all continuing applications thereof, including divisions, substitutions, and continuations-in-part (but only to the extent the claims thereof are entirely supported in the specification and entitled to the priority date of the parent application); and any patents issuing on said applications, including reissues and reexaminations, any extensions, and any corresponding foreign applications or patents; and

  (2) all patent rights associated with UCSD Case File [***]; any continuing applications thereof, including divisions, substitutions, and continuations-in-part (but only to the extent the claims thereof are entirely supported in the specification and entitled to the priority date of the parent application); and any patents issuing on said applications, including reissues and reexaminations, any extensions, and any corresponding foreign applications or patents.

   

  1.11	“Sublicense” means an agreement into which LICENSEE enters with a third party that is not an Affiliate for the purpose of (i) granting certain rights; (ii) granting an option to certain rights; or (iii) forbearing the exercise of any rights, granted to LICENSEE under this Agreement.  

   

  1.12	“Sublicensing Revenue” means all issue and upfront fees, milestone payments, sums and valuable consideration, and similar license fees received by LICENSEE from its Sublicensees in consideration for the grant of a Sublicense, but excluding: 
 

  [***].

   

  1.13	“Sublicensee” means a third party with whom LICENSEE enters into a Sublicense.  

   

  1.14	“Term” means the period of time beginning on the Effective Date and ending on the expiration date of the longest-lived Patent Rights.

   

  1.15	“Territory” means world-wide where Patent Rights exist.

   

  	 

  ***Certain Confidential Information Omitted

  Page 5 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

   

  ARTICLE 2.  GRANTS

   

  2.1 License.  Subject to the limitations set forth in this Agreement and Sponsor’s Rights, UNIVERSITY hereby grants to LICENSEE, and LICENSEE hereby accepts, a license under Patent Rights to make and have made, to use and have used, to sell and have sold, to offer for sale, and to import and have imported Licensed Products and to practice Licensed Methods, in the Field within the Territory and during the Term. LICENSEE may extend such license to Affiliates, provided that the LICENSEE is responsible for such Affiliates meeting their obligations under this License. 

   

  The license granted herein is exclusive for Patent Rights within the Field. 

    

  2.2 Sublicense.  

   

  (a) The license granted in Section 2.1 includes the right of LICENSEE to grant Sublicenses to third parties during the Term but only for as long as the license is exclusive.

   

  (b) With respect to Sublicense granted pursuant to Paragraph 2.2(a), LICENSEE shall:

   

  (i)not receive, or agree to receive, anything of value in lieu of cash as consideration from a third party under a Sublicense granted pursuant to Paragraph 2.2(a) without the express written consent of UNIVERSITY; 

   

  (ii) to the extent applicable, include all of the rights of and obligations due to UNIVERSITY and contained in this Agreement;

   

  (iii) promptly provide UNIVERSITY with a copy of each Sublicense issued; and

   

  (iv) collect and guarantee payment of all payments due, directly or indirectly, to UNIVERSITY from Sublicensees and summarize and deliver all reports due, directly or indirectly, to UNIVERSITY from Sublicensees.

   

  (c)  Upon termination of this Agreement for any reason, UNIVERSITY may terminate a Sublicensee but may allow LICENSEE to assign to UNIVERSITY any Sublicenses provided a) that the Sublicensee is in good standing upon termination of this Agreement with Licensee; b) the Sublicensee is not currently involved in litigation as an adverse party to the UNIVERSITY; and c) the Sublicensee is not operating in countries that UNIVERSITY is unable to do business with.  In no case, however, will UNIVERSITY be bound by duties and obligations contained in any Sublicense that extends beyond the duties and obligations of the UNIVERSITY set forth in this Agreement. If a Sublicense survives, the Sublicensee will promptly agree in writing to be bound by the terms of this Agreement, including but not limited to, in lieu of the payment obligations under the applicable Sublicense agreement, payment to the UNIVERSITY of milestone, earned royalty, patent reimbursement, and Sublicense fees required under Article 3.  If there is more than one Sublicense 

  	 

  ***Certain Confidential Information Omitted

  Page 6 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  that survives the termination of this Agreement, the payment obligations described above may be prorated among the Sublicenses.

   

  (d)  Mandatory Sublicensing:

   

  (I) At any time [***] from the Effective Date, if LICENSEE [***], then UNIVERSITY shall give notice to LICENSEE.  LICENSEE shall, within [***] of such notice, either (i) complete a Sublicense grant to a third party of a scope that would permit the third party to develop and commercialize a Licensed Product of interest to the third party as set forth in the development plan, or (ii) provide UNIVERSITY a detailed plan acceptable to UNIVERSITY for the development, manufacture and commercialization of a product in such area of usage.  LICENSEE shall begin actual implementation of, and maintain, such a plan immediately.  Such plan shall become part of the terms of this Agreement.  If LICENSEE does not either (i) complete a Sublicense grant or (ii) demonstrate implementation of said development plan within [***] of receipt of such notice from UNIVERSITY, then UNIVERSITY shall have the right to exclude such indication from LICENSEE’s Field.

   

  (II) In the event that LICENSEE and the third party are unable to reach agreement and LICENSEE does not grant a Sublicense to the third party within [***] after the notice specified in the above paragraph of 3.3(c), or refuses to grant such Sublicense under reasonable terms, then LICENSEE shall promptly submit to UNIVERSITY a written report specifying the license terms proposed by the third party and a written justification for the LICENSEE's refusal or failure to grant such Sublicense.  If UNIVERSITY [***].

   

  2.3 Reservation of Rights. UNIVERSITY reserves the right to: 

   

  (a) use the Invention and Patent Rights for educational and research purposes;

   

  (b) publish or otherwise disseminate any information about the Invention at any time; and

   

  (c) allow other nonprofit institutions to use and publish or otherwise disseminate any information about Invention and Patent Rights for educational and research purposes.

   

   

  ARTICLE 3.  CONSIDERATION

   

  3.1 Fees and Royalties.  The parties hereto understand that the fees and royalties payable by LICENSEE to UNIVERSITY under this Agreement are partial consideration for the license granted herein to LICENSEE under Patent Rights.  LICENSEE shall pay UNIVERSITY:

   

  (a) a license issue fee of ten thousand dollars (US$10,000), five thousand (US$5,000) dollars of which will be paid [***] after the Effective Date, and the balance of which will be paid within [***] after the Effective Date;

   

  	 

  ***Certain Confidential Information Omitted

  Page 7 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  (b) license maintenance fees of [***] per year and payable on the first anniversary of the Effective Date and annually thereafter on each anniversary; provided however, that LICENSEE’s obligation to pay this fee shall end on the date when LICENSEE is commercially selling a Licensed Product;

   

  Remainder of page intentionally left blank. 

   

  	 

  ***Certain Confidential Information Omitted

  Page 8 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  (c) LICENSEE shall pay UNIVERSITY the following milestone payments according to the following schedule of events:

   

  			
	 
	Amount in US dollars
	Event

	A
	$[***]
	[***]

	B
	$[***]
	[***]

	C
	$[***]
	[***]

	D
	$[***]
	[***]

	E
	$[***]
	[***]

	F
	$[***]
	Upon cumulative Net Sales of $[***]in US dollars

	G
	$[***]
	Upon cumulative Net Sales of $[***] in US dollars 

	H
	$[***]
	Upon cumulative Net Sales of $[***] in US dollars

	I
	$[***]
	Upon cumulative Net Sales of $[***] in US dollars

	J
	$[***]
	Upon cumulative Net Sales of $[***] in US dollars

   

  (d) an earned royalty (“Earned Royalty”) of [***] on Net Sales of Licensed Products by LICENSEE, Sublicensees, and/or Affiliates, provided, however, that the earned royalty due on Net Sales of Combination Product by LICENSEE and/or its Affiliate(s) shall be calculated as below:

   

  	Earned Royalties due UNIVERSITY = [***], where:

   

  [***]; and

   

  [***], that satisfy the requirements outlined in Paragraph 1.2 (“Combination Products”).  For any products in B for which LICENSEE has reduced its earned royalties payable to UNIVERSITY under 3.1(d), this provision shall not apply.

   

  Remainder of page intentionally left blank. 

   

   

  	 

  ***Certain Confidential Information Omitted

  Page 9 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  (I) In the event LICENSEE is required to pay royalties to one or more third parties for patent rights necessary to make, use or sell Licensed Products, LICENSEE may deduct $[***] from the earned royalties payable to UNIVERSITY for every $[***] LICENSEE actually pays to said third parties; provided, however, in no event shall the amount payable to UNIVERSITY be less than [***]% of the amount otherwise due, unless the Parties agree to otherwise in writing.

   

  (e) [***] of all Sublicense Revenue Payments received by LICENSEE from its Sublicensees that are not earned royalties or otherwise excluded under Section 1.11. 

   

  (f) beginning the calendar year of commercial sales of the first Licensed Product by LICENSEE, Sublicensee, or an Affiliate, and if the total Earned Royalties paid by LICENSEE under Paragraph 3.1(c) to UNIVERSITY in any such year cumulatively amounts to less than [***], LICENSEE shall pay to UNIVERSITY on or before February 28 each year the difference between [***] and the total Earned Royalty paid by LICENSEE for such year under Paragraph 3.1(d) (the “Minimum Annual Royalty”); provided however, that for the year of commercial sales of the first Licensed Product, the amount of minimum annual royalty payable shall be pro-rated for the number of months remaining in that calendar year.

   

  All fees and royalty payments specified in Paragraphs 3.1(a) through 3.1(f) above shall be paid by LICENSEE pursuant to Paragraph 4.3 and shall be delivered by LICENSEE to UNIVERSITY as noted in Paragraph 10.1.  

   

  3.2 Patent Costs. LICENSEE shall reimburse UNIVERSITY for any unreimbursed past Patent Costs (incurred prior to the Effective Date). LICENSEE shall reimburse UNIVERSITY all future (on or after the Effective Date), Patent Costs incurred during the Term and in the Territory within [***] following the date an itemized invoice is sent from UNIVERSITY to LICENSEE. 

   

  3.3 Due Diligence.

   

  (a)  LICENSEE shall, either directly or through its Affiliate(s) or Sublicensee(s):

   

  (i) diligently proceed with the development, manufacture and sale of Licensed Products;

   

  (ii) annually spend not less than [***] for the development of Licensed Products during the first [***] years of this Agreement.  LICENSEE may, at its sole option, [***];

   

  (iii) complete the diligence obligations in Exhibit A herein.

   

  (iv) market Licensed Products in the United States within [***] of receiving regulatory approval to market such Licensed Products;

   

  	 

  ***Certain Confidential Information Omitted

  Page 10 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  (v) fill the market demand for Licensed Products following commencement of marketing at any time during the term of this Agreement; and

   

  (vi) obtain all necessary governmental approvals for the manufacture, use and sale of Licensed Products.

   

  (b) If LICENSEE fails to perform any of its obligations specified in Paragraphs 3.3(a)(i)-(vi), then UNIVERSITY shall have the right and option to either terminate this Agreement or change LICENSEE’s exclusive license to a nonexclusive license.  This right, if exercised by UNIVERSITY, supersedes the rights granted in Article 2.

   

   

  ARTICLE 4.  REPORTS, RECORDS AND PAYMENTS

   

  4.1 Reports.  

   

  (a) Progress Reports. LICENSEE will diligently keep UNIVERSITY updated, by email, and as requested, by teleconference, regarding substantial progress developing Products.  In addition, upon the written request of UNIVERSITY, beginning [***] after Effective Date and ending on the date of first commercial sale of a Licensed Product in the United States, LICENSEE shall report to UNIVERSITY progress covering LICENSEE’s (and Affiliate’s and Sublicensee’s) activities for the preceding year to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same.  Such annual reports shall be due within [***] of the reporting period and include a summary of work completed, summary of work in progress, current schedule of anticipated events or milestones, market plans for introduction of Licensed Products, and summary of resources (dollar value) spent in the reporting period. The reports referred to in this Section 4.1(a) should be marked with the following title and case number: “License Agreement between UCSD and Palisade Bio, Inc., for [***].” Reports shall be submitted as attachment to UCSD’s email address: [***].

   

  Remainder of page intentionally left blank. 

   

   

  	 

  ***Certain Confidential Information Omitted

  Page 11 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  (b) Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual royalty reports on or before February 28 of each year.  Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year and shall show:

   

             		(i)  the date of first commercial sale of a Licensed Product in each country;

   

  (ii) the gross sales, deductions as provided in Paragraph 1.7 (Net Sales), and Net Sales during the most recently completed calendar year and the royalties, in US dollars, payable with respect thereto;

   

  (iii) the number of each type of Licensed Product sold;

   

  (iv) Sublicense fees and royalties received during the most recently completed calendar year in US dollars, payable with respect thereto;

   

  (v) the method used to calculate the royalties; and

   

  (vi) the exchange rates used.

   

  If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Section 4.1(b) should be marked with the following title and case number: “License Agreement between UCSD and UCSD and Palisade Bio, Inc., for case [***].” Reports shall be submitted as attachment to UCSD’s email address: [***].

   

  (c) Timely Reports. LICENSEE acknowledges the important value that timely reporting provides in the UNIVERSITY’s effective management of its rights under this Agreement.  LICENSEE further acknowledges that failure to render the reports required under this Section 4.1 may harm UNIVERSITY’s ability to manage its rights under this Agreement.  As such, reports not submitted by the required due date under this Section 4.1 will cause to be due by LICENSEE to UNIVERSITY a late reporting fee of [***] per month until such report, compliant with the requirements of this Section 4.1, is received by UNIVERSITY.  Payment of this fee is subject to Section 4.3, Section 7.1 and Paragraph 10.1 herein.

   

  4.2 Records & Audits.

   

  (a) LICENSEE shall keep, and shall require its Affiliates and Sublicensees to keep, accurate and correct records of all Licensed Products manufactured, used, and sold, and Sublicense fees received under this Agreement.  Such records shall be retained by LICENSEE for at least [***] years following a given reporting period.

  (b) All records shall be available during normal business hours for inspection at the expense of UNIVERSITY by UNIVERSITY’s Internal Audit Department or by a Certified Public Accountant selected by UNIVERSITY and in compliance with the other terms of this Agreement for 

  	 

  ***Certain Confidential Information Omitted

  Page 12 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  the sole purpose of verifying reports and payments or other compliance issues.  Such inspector shall not disclose to UNIVERSITY any information other than information relating to the accuracy of reports and payments made under this Agreement or other compliance issues.  In the event that any such inspection shows an under reporting and underpayment in excess of [***] for any [***] period, then LICENSEE shall pay the cost of the audit as well as any additional sum that would have been payable to UNIVERSITY had the LICENSEE reported correctly, plus an interest charge at a rate of [***] per year.  Such interest shall be calculated from the date the correct payment was due to UNIVERSITY up to the date when such payment is actually made by LICENSEE.  For underpayment not in excess of [***] for any [***] period, LICENSEE shall pay the difference within [***] without interest charge or inspection cost.

   

  4.3 Payments.

   

  (a) All fees, reimbursements and royalties due UNIVERSITY shall be paid in United States dollars and all checks (should payment by wire not be possible) shall be made payable to “The Regents of the University of California”, referencing UNIVERSITY’s taxpayer identification number, [***], and sent to UNIVERSITY according to Paragraph 10.1 (Correspondence).  When Licensed Products are sold in currencies other than United States dollars, LICENSEE shall first determine the earned royalty in the currency of the country in which Licensed Products were sold and then convert the amount into equivalent United States funds, using the exchange rate quoted in the Wall Street Journal on the last business day of the applicable reporting period.

   

  (b) Royalty Payments.  

   

  (i) Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered to a third party or Affiliate.

   

  (ii) LICENSEE shall pay earned royalties annually on or before February 28 of each calendar year.  Each such payment shall be for Earned Royalties and fees accrued within LICENSEE’s most recently completed calendar year.

   

  (iii) Royalties earned on sales occurring or under Sublicense granted pursuant to this Agreement in any country outside the United States shall [***].  

   

  Remainder of page intentionally left blank. 

   

   

  	 

  ***Certain Confidential Information Omitted

  Page 13 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  (iv) If at any time legal restrictions prevent the prompt remittance of part or all royalties by LICENSEE with respect to any country where a Licensed Product is sold or a Sublicense is granted pursuant to this Agreement, LICENSEE shall convert the amount owed to UNIVERSITY into US currency and shall pay UNIVERSITY directly from its US sources of funds for as long as the legal restrictions apply.

   

  (v) In the event that any patent or patent claim within Patent Rights is held invalid in a final decision by a patent office from which no appeal or additional patent prosecution has been or can be taken, or by a court of competent jurisdiction and last resort and from which no appeal has or can be taken, all obligation to pay royalties based solely on that patent or claim or any claim patentably indistinct therefrom shall cease as of the date of such final decision.  LICENSEE shall not, however, be relieved from paying any royalties that accrued before the date of such final decision, that are based on another patent or claim not involved in such final decision.

   

  (vi) Royalty payments under Article 3, recoveries and settlements under Article 5, and royalty reports under 4.1(b) shall be rendered for any and all Licensed Products even if due after expiration of the Agreement.  If no Patent Rights existed in the Territory at the time of any making, use, sale, offer for sale, or import, then no royalty payments or royalty reports shall be due.

   

  (c) Late Payments. In the event royalty, reimbursement and/or fee payments are not received by UNIVERSITY when due, LICENSEE shall pay to UNIVERSITY interest charges at a rate of [***] per year.  Such interest shall be calculated from the date payment was due until actually received by UNIVERSITY.

   

   

  ARTICLE 5.  PATENT MATTERS

   

  5.1 Patent Prosecution and Maintenance.

  (a) Provided that LICENSEE has reimbursed UNIVERSITY for Patent Costs pursuant to Paragraph 3.2, UNIVERSITY shall diligently prosecute and maintain the United States and, if available, foreign patents, and applications in Patent Rights using counsel of its choice.  For purposes of clarity, if LICENSEE is not current in reimbursing UNIVERSITY for such patent prosecution costs, UNIVERSITY shall have no obligation to incur any new Patent Costs under this Agreement or to further prosecute Patent Rights or file any new patents under Patent Rights.  UNIVERSITY shall keep LICENSEE reasonably informed of the prosecution of Patent rights, will provide LICENSEE with copies of all relevant documentation relating to such prosecution and give LICENSEE time to review and comment (and LICENSEE shall keep this documentation confidential).  The counsel shall take instructions only from UNIVERSITY, and all patents and patent applications in Patent Rights shall be assigned solely to UNIVERSITY. UNIVERSITY will take into consideration, however, any comments from LICENSEE bearing on the protection of Licensed Products or Licensed Methods.  UNIVERSITY shall in any event control all patent filings and all patent prosecution decisions and related filings (e.g. responses to office actions) shall be at 

  	 

  ***Certain Confidential Information Omitted

  Page 14 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  UNIVERSITY’s final discretion (prosecution includes, but is not limited to, interferences, oppositions and any other inter partes matters originating in a patent office).  

  (b) UNIVERSITY shall consider amending any patent application in Patent Rights to include claims reasonably requested by LICENSEE to protect the products contemplated to be sold by LICENSEE under this Agreement.

   

  (c) LICENSEE may elect to terminate its reimbursement obligations with respect to any patent application or patent in Patent Rights upon [***] written notice to UNIVERSITY.  UNIVERSITY shall use reasonable efforts to curtail further Patent Costs for such application or patent when such notice of termination is received from LICENSEE.  UNIVERSITY, in its sole discretion and at its sole expense, may continue prosecution and maintenance of said application or patent, and LICENSEE shall have no further license with respect thereto.  Non-payment of any portion of Patent Costs with respect to any application or patent may be deemed by UNIVERSITY as an election by LICENSEE to terminate its reimbursement obligations with respect to such application or patent.  UNIVERSITY is not obligated at any time to file, prosecute, or maintain Patent Rights in a country, where, for that country’s patent application LICENSEE is not paying Patent Costs, or to file, prosecute, or maintain Patent Rights to which LICENSEE has terminated its license hereunder.

   

  5.2 Patent Infringement.

   

  (a) In the event that UNIVERSITY (to the extent of the actual knowledge of the licensing professional responsible for the administration of this Invention) or LICENSEE learns of infringement of potential commercial significance of any patent licensed under this Agreement, the knowledgeable party will provide the other (i) with written notice of such infringement and (ii) with any evidence of such infringement available to it (the “Infringement Notice”).  During the period in which, and in the jurisdiction where, LICENSEE has exclusive rights under this Agreement, neither UNIVERSITY nor LICENSEE will notify a third party (including the infringer) of infringement or put such third party on notice of the existence of any Patent Rights without first obtaining consent of the other.  If LICENSEE notifies a third party of infringement or puts such third party on notice of the existence of any Patent Rights with respect to such infringement without first obtaining the written consent of UNIVERSITY and UNIVERSITY is sued in declaratory judgment, UNIVERSITY shall have the right to terminate this Agreement immediately without the obligation to provide [***] notice as set forth in Paragraph 7.1.  Both UNIVERSITY and LICENSEE will use their diligent efforts to cooperate with each other to terminate such infringement without litigation.  

   

  (b) If infringing activity of potential commercial significance by the infringer has not been abated within [***] following the date the Infringement Notice takes effect LICENSEE may institute suit for patent infringement against the infringer.  UNIVERSITY may voluntarily join such suit at its own expense, but may not thereafter commence suit against the infringer for the acts of infringement that are the subject of LICENSEE’s suit or any judgment rendered in that suit.  LICENSEE may not join UNIVERSITY in a suit initiated by LICENSEE without UNIVERSITY’S prior written consent.  If, in a suit initiated by LICENSEE, UNIVERSITY is involuntarily joined other than by LICENSEE, 

  	 

  ***Certain Confidential Information Omitted

  Page 15 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  LICENSEE will pay any costs incurred by UNIVERSITY arising out of such suit, including but not limited to, any legal fees of counsel that UNIVERSITY selects and retains to represent it in the suit.

   

  (c) If, within [***] following the date the Infringement Notice takes effect, infringing activity of potential commercial significance by the infringer has not been abated and if LICENSEE has not brought suit against the infringer, UNIVERSITY may institute suit for patent infringement against the infringer.  If UNIVERSITY institutes such suit, LICENSEE may not join such suit without UNIVERSITY’S consent and may not thereafter commence suit against the infringer for the acts of infringement that are the subject of UNIVERSITY’S suit or any judgment rendered in that suit.

   

  (d) Notwithstanding anything to the contrary in this Agreement, in the event that the infringement or potential infringement pertains to an issued patent included within the Patent Rights and written notice is given under any statute expediting litigation (e.g. the Drug Price Competition and Patent Term Restoration Act of 1984 and/or foreign counterparts of this Law) ("Act"), then the party in receipt of such notice under the Act (in the case of UNIVERSITY to the extent of the actual knowledge of the licensing officer responsible for the administration of this Agreement) shall provide the Infringement Notice to the other party promptly. If the time period is such that the LICENSEE will lose the right to pursue legal remedy for infringement by not notifying a third party or by not filing suit, the notification period and the time period to file suit will be accelerated to within [***] of the date of such notice under the Act to either party.

   

  (e) Any recovery or settlement received in connection with any suit will first be shared by UNIVERSITY and LICENSEE equally to cover the litigation costs each incurred, and next shall be paid to UNIVERSITY or LICENSEE to cover any litigation costs it incurred in excess of the litigation costs of the other.  In any suit initiated by LICENSEE, any recovery in excess of litigation costs will be shared between LICENSEE and UNIVERSITY as follows:  (i) for any recovery other than amounts paid for willful infringement:  (A) UNIVERSITY will receive [***] of the recovery if UNIVERSITY was not a party in the litigation and did not incur any litigation costs; (B) UNIVERSITY will receive [***] of the recovery if UNIVERSITY was a party in the litigation, but did not incur any litigation costs, including the provisions of Paragraph 5.2(b) above, or (C) UNIVERSITY will receive [***] of the recovery if UNIVERSITY incurred any litigation costs in connection with the litigation;  and (ii) for any recovery for willful infringement, UNIVERSITY will receive [***] of the recovery.  In any suit initiated by UNIVERSITY, any recovery in excess of litigation costs will [***].  UNIVERSITY and LICENSEE agree to be bound by all determinations of patent infringement, validity, and enforceability (but no other issue) resolved by any adjudicated judgment in a suit brought in compliance with this Section 5.2.

   

  (f) Any agreement made by LICENSEE for purposes of settling litigation or other dispute shall comply with the requirements of Section 2.2 (Sublicenses) of this Agreement.  

   

  (g) Each party will cooperate with the other in litigation proceedings instituted hereunder but at the expense of the party who initiated the suit (unless such suit is being jointly prosecuted by the parties).  

   

  	 

  ***Certain Confidential Information Omitted

  Page 16 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  (h) Any litigation proceedings will be controlled by the party bringing the suit, except that UNIVERSITY may be represented by counsel of its choice in any suit brought by LICENSEE.

   

  5.3 Patent Marking. LICENSEE shall mark all Licensed Products made, used or sold under the terms of this Agreement, or their containers, in accordance with the applicable patent marking laws.  LICENSEE shall be responsible for all monetary and legal liabilities arising from or caused by (i) failure to abide by applicable patent marking laws and (ii) any type of incorrect or improper patent marking.  

   

   

  ARTICLE 6.  GOVERNMENTAL MATTERS

   

  6.1 Governmental Approval or Registration.  If this Agreement or any associated transaction is required by the law of any nation to be either approved or registered with any governmental agency, LICENSEE shall assume all legal obligations to do so.  LICENSEE shall notify UNIVERSITY if it becomes aware that this Agreement is subject to a United States or foreign government reporting or approval requirement.  LICENSEE shall make all necessary filings and [***].

   

  6.2 Export Control Laws. LICENSEE shall observe all applicable United States and foreign laws with respect to the transfer of Licensed Products and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations and the Export Administration Regulations.

   

   

  ARTICLE 7.  TERMINATION OR EXPIRATION OF THE AGREEMENT

   

  7.1 Termination by UNIVERSITY.  

   

  (a) If LICENSEE fails to perform or violates any term of this Agreement, then UNIVERSITY may give written notice of default (“Notice of Default”) to LICENSEE.  If LICENSEE fails to cure the default within sixty (60) days of the Notice of Default, UNIVERSITY may terminate this Agreement and the license granted herein by a second written notice (“Notice of Termination”) to LICENSEE.  If a Notice of Termination is sent to LICENSEE, this Agreement shall automatically terminate on the effective date of that notice.  Termination shall not relieve LICENSEE of its obligation to pay any fees owed at the time of termination and shall not impair any accrued right of UNIVERSITY.  During the term of any such Notice of Default or period to cure, to the extent the default at issue is a failure to pay past or ongoing Patent Costs as provided for under this Agreement, UNIVERSITY shall have no obligation to incur any new Patent Costs under this Agreement and shall have no obligation to further prosecute Patent Rights or file any new patents under Patent Rights.

   

  (b) This Agreement will terminate immediately, without the obligation to provide sixty (60) days’ notice as set forth in Paragraph 7.1(a), if LICENSEE files a claim including in any way the assertion that any portion of UNIVERSITY’s Patent Rights is invalid or unenforceable where the 

  	 

  ***Certain Confidential Information Omitted

  Page 17 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  filing is by the LICENSEE, a third party on behalf of the LICENSEE, or a third party at the written urging of the LICENSEE.

   

  c) This Agreement shall automatically terminate without the obligation to provide sixty (60) days’ notice as set forth in Paragraph 7.1(a) if LICENSEE becomes insolvent or files for bankruptcy that includes asset liquidation.

   

  7.2 Termination by LICENSEE.  

   

  (a) LICENSEE shall have the right at any time and for any reason to terminate this Agreement upon a ninety (90) day written notice to UNIVERSITY.  Said notice shall state LICENSEE’s reason for terminating this Agreement.

   

  (b) Any termination under Paragraph 7.2(a) shall not relieve LICENSEE of any obligation or liability accrued under this Agreement prior to termination or rescind any payment made to UNIVERSITY or action by LICENSEE prior to the time termination becomes effective.  Termination shall not affect in any manner any rights of UNIVERSITY arising under this Agreement prior to termination.

   

  7.3 Survival on Termination or Expiration. The following Paragraphs and Articles shall survive the termination or expiration of this Agreement:

   

  (a) Article 4 (REPORTS, RECORDS AND PAYMENTS);

   

  (b) Paragraph 7.4 (Disposition of Licensed Products on Hand);

   

  (c) Article 8 (LIMITED WARRANTY AND INDEMNIFICATION);

    

  (d) Article 9 (USE OF NAMES AND TRADEMARKS);

   

  (e) Paragraph 10.2 hereof (Secrecy); 

   

  (f) Paragraph 10.5 (Failure to Perform); and

   

  (g) Paragraph 10.6 (Governing Laws).

   

  7.4 Disposition of Licensed Products on Hand. Upon termination of this Agreement, LICENSEE may dispose of all previously made or partially made Licensed Product within a period of one hundred and twenty (120) days of the effective date of such termination provided that the sale of such Licensed Product by LICENSEE, its Sublicensees, or Affiliates shall be subject to the terms of this Agreement, including but not limited to the rendering of reports and payment of royalties required under this Agreement.

   

   

  	 

  ***Certain Confidential Information Omitted

  Page 18 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  ARTICLE 8.  LIMITED WARRANTY AND INDEMNIFICATION

   

  8.1 Limited Warranty.

   

  Remainder of page intentionally left blank. 

  (a)  To the extent of the actual knowledge of the licensing professional with responsibility of this agreement and  as of the Effective Date, UNIVERSITY warrants to the LICENSEE that it has the lawful right to grant this license.

   

  (b) The license granted herein is provided “AS IS” and without WARRANTY OF MERCHANTABILITY or WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE or any other warranty, express or implied.  UNIVERSITY makes no representation or warranty that the Licensed Product, Licensed Method or the use of Patent Rights will not infringe any other patent or other proprietary rights. 

   

  (c) UNIVERSITY WILL NOT BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT, OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER SPECIAL DAMAGES SUFFERED BY LICENSEE, SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF UNIVERSITY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.  ALSO, UNIVERSITY WILL NOT BE LIABLE FOR ANY DIRECT DAMAGES SUFFERED BY LICENSEE, SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO PATENT RIGHTS TO THE EXTENT ASSIGNED, OR OTHERWISE LICENSED, BY UNIVERSITY’S INVENTORS TO THIRD PARTIES.  

   

  (d) Nothing in this Agreement shall be construed as:

   

  (i) a warranty or representation by UNIVERSITY as to the validity or scope of any Patent Rights;

   

  (ii) a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement is or shall be free from infringement of patents of third parties;

   

  (iii) an obligation to bring or prosecute actions or suits against third parties for patent infringement except as provided in Section 5.2 hereof;

   

  (iv) conferring by implication, estoppel or otherwise any license or rights under any patents of UNIVERSITY other than Patent Rights as defined in this Agreement, regardless of whether those patents are dominant or subordinate to Patent Rights; or

  	 

  ***Certain Confidential Information Omitted

  Page 19 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

   

  (v) an obligation to furnish any know-how not provided in Patent Rights.

   

  8.2 Indemnification.

   

  Remainder of page intentionally left blank. 

   

   

  (a) LICENSEE will, and will require Sublicensees to, indemnify, hold harmless, and defend UNIVERSITY and its officers, employees, and agents; the sponsors of the research that led to the Invention; and the inventors of patents or patent applications under Patent Rights, and their employers; against any and all claims, suits, losses, damages, costs, fees, and expenses resulting from, or arising out of, the exercise of this license or any Sublicense.  This indemnification will include, but will not be limited to, any product liability.

   

  (b) LICENSEE, at its sole cost and expense, shall insure its activities in connection with the work under this Agreement and obtain, keep in force and maintain insurance or an equivalent program of self insurance as follows:

   

  (i) comprehensive or commercial general liability insurance (contractual liability included) with limits of at least: (A) each occurrence, [***]; (B) products/completed operations aggregate, [***]; (C) personal and advertising injury, [***]; and (D) general aggregate [***].  If the above insurance is written on a claims-made form, it shall continue for [***] following termination or expiration of this Agreement. The insurance shall have a retroactive date of placement prior to or coinciding with the Effective Date;

   

  (ii) Worker’s Compensation as legally required in the jurisdiction in which the LICENSEE is doing business; and

   

  (iii) the coverage and limits referred to above shall not in any way limit the liability of LICENSEE.  

   

  (c) LICENSEE shall furnish UNIVERSITY with certificates of insurance showing compliance with all requirements.  Such certificates shall: (i) provide for [***] advance written notice to UNIVERSITY of any modification; (ii) indicate that UNIVERSITY has been endorsed as an additionally insured party under the coverage referred to above; and (iii) include a provision that the coverage shall be primary and shall not participate with nor shall be excess over any valid and collectable insurance or program of self-insurance carried or maintained by UNIVERSITY.

   

  (d) UNIVERSITY shall notify LICENSEE in writing of any claim or suit brought against UNIVERSITY in respect of which UNIVERSITY intends to invoke the provisions of this Article.  LICENSEE shall keep UNIVERSITY informed on a current basis of its defense of any claims under this Article.  LICENSEE will not settle any claim against UNIVERSITY without UNIVERSITY’s 

  	 

  ***Certain Confidential Information Omitted

  Page 20 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  written consent, where (a) such settlement would include any admission of liability or admission of wrong doing on the part of the indemnified party, (b) such settlement would impose any restriction on UNIVERSITY/indemnified party’s conduct of any of its activities, or (c) such settlement would not include an unconditional release of UNIVERSITY/indemnified party from all liability for claims that are the subject matter of the settled claim.

   

  Remainder of page intentionally left blank. 

   

   

  	 

  ***Certain Confidential Information Omitted

  Page 21 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  ARTICLE 9.  USE OF NAMES AND TRADEMARKS

   

  9.1 Except as provided in 9.3, nothing contained in this Agreement confers any right to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of either party hereto (including contraction, abbreviation or simulation of any of the foregoing).  Unless required by law, the use by LICENSEE of the name, “The Regents of the University of California” or the name of any campus of the University of California in advertising, publicity, or other promotional activities is prohibited, without the express written consent of UNIVERSITY.

   

  9.2 UNIVERSITY may disclose to the Inventors the terms and conditions of this Agreement upon their request.  If such disclosure is made, UNIVERSITY shall request the Inventors not disclose such terms and conditions to others.

   

  9.3 UNIVERSITY may acknowledge the existence of this Agreement and the extent of the grant in Article 2 to third parties, but UNIVERSITY shall not disclose the financial terms of this Agreement to third parties, except where UNIVERSITY is required by law to do so, such as under the California Public Records Act.  LICENSEE hereby grants permission for UNIVERSITY (including UCSD) to include LICENSEE’s name and a link to LICENSEE’s website in UNIVERSITY’s and UCSD’s annual reports and on UNIVERSITY’s (including UCSD’s) websites that showcase technology transfer-related stories.

   

  9.4. LICENSEE may not use the name of the University of California, UCSD, or of any UCSD employee, in a manner that reasonably could constitute an endorsement of a commercial product or service.  LICENSEE may use such names for other purposes, even if commercially motivated, provided that (1) the use is limited to accurately reporting factual events or occurrences, and (2) any reference to the name of the University of California, UCSD or any UCSD employees, in press releases or similar materials intended for public release is approved by UCSD in advance.

   

   

  ARTICLE 10.  MISCELLANEOUS PROVISIONS

   

  10.1 Correspondence. Any notice or payment required to be given to either party under this Agreement shall be deemed to have been properly given and effective: 

   

  (a)  on the date of delivery if delivered in person;

   

  (b) five (5) days after mailing if mailed by first-class or certified mail, postage paid, to the respective addresses given below, or to such other address as is designated by written notice given to the other party; or 

   

  (c) upon confirmation by recognized national overnight courier, or confirmed electronic mail, to the following addresses of the parties.

            

  	 

  ***Certain Confidential Information Omitted

  Page 22 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  	If sent to LICENSEE:

   

  		Palisade Bio, Inc.

  [***]

  		 

  	If sent to UNIVERSITY by mail:

  		University of California, San Diego

  		Office of Innovation and Commercialization

  	 	[***]

   

        	If sent to UNIVERSITY by overnight delivery:   

  		University of California, San Diego

  		Office of Innovation and Commercialization

  		[***]

         

  10.2 Secrecy.	 

   

  (a) “Confidential Information” shall mean information, relating to the Invention and disclosed by UNIVERSITY to LICENSEE during the term of this Agreement, which if disclosed in writing shall be marked “Confidential”, or if first disclosed otherwise, shall within [***] of such disclosure be reduced to writing by UNIVERSITY and sent to LICENSEE:

   

  (b)  LICENSEE shall:

  (i) use the Confidential Information for the sole purpose of performing under the terms of this Agreement;

   

  (ii) safeguard Confidential Information against disclosure to others with the same degree of care as it exercises with its own data of a similar nature;

   

  (iii) not disclose Confidential Information to others (except to its employees, agents or consultants who are bound to LICENSEE by a like obligation of confidentiality) without the express written permission of UNIVERSITY, except that LICENSEE shall not be prevented from using or disclosing any of the Confidential Information that: 

   

  (A)	LICENSEE can demonstrate by written records was previously known to it; 

   

  (B)	is now, or becomes in the future, public knowledge other than through acts or omissions of LICENSEE; 

    

  (C)	is lawfully obtained by LICENSEE from sources independent of UNIVERSITY; or

   

  	 

  ***Certain Confidential Information Omitted

  Page 23 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  (D)	is required to be disclosed by law or a court of competent jurisdiction; and

   

  (c) The secrecy obligations of LICENSEE with respect to Confidential Information shall continue for a period ending five (5) years from the termination date of this Agreement.

   

  10.3 Assignability. This Agreement may be assigned by UNIVERSITY, but is personal to LICENSEE and assignable by LICENSEE only with the written consent of UNIVERSITY; provided, however, that LICENSEE may assign this Agreement and its rights and the license granted herein without UNIVERSITY’S prior written consent in conjunction with the sale or transfer of all, or substantially all of LICENSEE’s business or assets relating to this Agreement, whether by sale of stock, sale of assets, merger, or otherwise, [***].

  10.4 No Waiver. No waiver by either party of any breach or default of any covenant or agreement set forth in this Agreement shall be deemed a waiver as to any subsequent and/or similar breach or default.

   

  10.5 Failure to Perform. In the event of a failure of performance due under this Agreement and if it becomes necessary for either party to undertake legal action against the other on account thereof, then the prevailing party shall be entitled to reasonable attorneys’ fees in addition to costs and necessary disbursements.

   

  10.6 Governing Laws.  THIS AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, but the scope and validity of any patent or patent application shall be governed by the applicable laws of the country of the patent or patent application.

   

  10.7 Force Majeure. A party to this Agreement may be excused from any performance required herein if such performance is rendered impossible or unfeasible due to any catastrophe or other major event beyond its reasonable control, including, without limitation, earthquake, wildfire, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other serious labor disputes; and floods, fires, explosions, or other natural disasters.  When such events have abated, the non-performing party’s obligations herein shall resume.

   

  10.8 Headings. The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.

   

  10.9 Entire Agreement. This Agreement embodies the entire understanding of the parties and supersedes all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof.

   

  10.10 Amendments. No amendment or modification of this Agreement shall be valid or binding on the parties unless made in writing and signed on behalf of each party.

   

  	 

  ***Certain Confidential Information Omitted

  Page 24 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  10.11 Severability. In the event that any of the provisions contained in this Agreement is held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if the invalid, illegal, or unenforceable provisions had never been contained in it.

   

  10.12 Counterparts. The parties agree that this Agreement may be executed by electronic copies and in two (2) or more counterparts, each of which shall be deemed an original and all of which together shall constitute but one and the same instrument. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used.  The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature.

   

   

  IN WITNESS WHEREOF, both UNIVERSITY and LICENSEE have executed this Agreement, in duplicate originals, by their respective and duly authorized officers on the day and year written.

   

   

  		
	PALISADE BIO, INC.
 
 
 
 
By: /s/ Thomas Hallam
(Signature)
 
Thomas Hallam, MBA, Ph.D.
Chief Executive Officer
 
 
 
Date: Jul 6, 2021
 
	THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA
 
 
 
By: /s/ Donna Shaw
(Signature)
 
Donna Shaw, CLP, Ph.D.
Associate Director-Office of Innovation and Commercialization
 
 
Date: 6/30/2021
 

   

   

  	 

  ***Certain Confidential Information Omitted

  Page 25 of  NUMPAGES  25

   

   

   

  

  EXHIBIT 10.5

  Exhibit A – Due Diligence Obligations

   

  LICENSEE shall complete the tasks or milestones set forth in the following schedule in relation to the Effective Date (ED):

   

  			
	#
	Description of activity for Licensed Product
	Months from ED / Event

	A
	Initiate analysis of human clinical samples
 
	Within [***]

	B
	Complete analysis of human samples
	Within [***]

	C
	Submission to Food & Drug Administration (or similar competent agency) an application seeking approval for marketing of a Licensed Product
	Within [***]

	D
	Food & Drug Administration (or similar competent agency) approval for marketing of a Licensed Product
	Within [***]of #C

	E
	First commercial sale of Licensed Products for use in the Field
	No later than [***] of #D

	F
	Achieve annual Net Sales of at least [***] 
	[***] after receiving regulatory approval from FDA for a Licensed Product for commercial use.

	G
	Achieve annual Net Sales of at least [***]
	[***] after receiving regulatory approval from FDA for a Licensed Product for a commercial use.

   

   

  	 

  ***Certain Confidential Information Omitted

  Page 26 of  NUMPAGES  25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]